GLP1R and familial pancreatic carcinoma: Patients receiving combination therapy that included GLP-1R agonists had a lower risk for pancreatic cancer when compared with those on single, non–GLP-1R therapy, but not when the combination therapy was compared with GLP-1R monotherapy (53), suggesting a specific antitumor effect of GLP-1R activation.